TERAVOLT: outcomes for patients with COVID-19 and lung cancer

• Date : 25/03/2021
• 13    
  0

Lung cancer screening in Latin America

• Date : 04/09/2021
• 11    
  0

Mechanisms of acquired resistance against immunotherapy

• Date : 25/03/2021
• 1    
  0

CheckMate 9LA: TMB and immune checkpoint inhibitor efficacy

• Date : 25/03/2021
• 1    
  0

COVID-19: impact on lung cancer treatment in the UK

• Date : 25/03/2021
• 0    
  0

KRYSTAL-1: adagrasib for KRAS-mutant NSCLC

• Date : 25/03/2021
• 0    
  0

Management of patients with PDL1-high advanced NSCLC

• Date : 25/03/2021
• 0    
  0

Fulfilling unmet supportive care needs of patients with lung cancer

• Date : 25/03/2021
• 0    
  0

Patterns of relapse after radiotherapy in SCLC and future treatment strategies

• Date : 25/03/2021
• 0    
  0

NICE approval of brigatinib in ALK-positive NSCLC

• Date : 25/03/2021
• 0    
  0

The rollout of genomic hubs in the UK

• Date : 25/03/2021
• 0    
  0

ctDNA NGS for treatment decision-making in NSCLC

• Date : 25/03/2021
• 0    
  0

KEYNOTE-407: 3-year follow-up of pembrolizumab plus chemo in NSCLC

• Date : 27/03/2021
• 0    
  0

Brain metastases and lung cancer: optimizing treatment using biomarkers

• Date : 27/03/2021
• 0    
  0

Exciting updates in radiotherapy at ELCC 2021

• Date : 27/03/2021
• 0    
  0

Future perspectives on radiation oncology in lung cancer

• Date : 27/03/2021
• 0    
  0

Using clinical trials to drive treatment approaches in lung cancer

• Date : 27/03/2021
• 0    
  0

Highlights from ELCC 2021

• Date : 27/03/2021
• 0    
  0

Update from a phase 1 study of AMG 757 in SCLC

• Date : 27/03/2021
• 0    
  0

Update from a Phase 1 study of AMG 757 in SCLC

• Date : 25/03/2021
• 0    
  0

KEYNOTE-407: pembrolizumab plus chemo improves OS and PFS in NSCLC

• Date : 25/03/2021
• 0    
  0

Lung cancer screening: NELSON and NLST

• Date : 25/03/2021
• 0    
  0

Surgery for oligometastatic lung cancer

• Date : 25/03/2021
• 0    
  0

Novel targets for NSCLC

• Date : 25/03/2021
• 0    
  0

Treating cancer during the COVID-19 pandemic

• Date : 25/03/2021
• 0    
  0

Roy Castle Lung Cancer: genomics and novel risk models

• Date : 25/03/2021
• 0    
  0

Upfront treatment of ROS1-rearranged NSCLC

• Date : 25/03/2021
• 0    
  0

Combining immunotherapy and radiotherapy to improve mesothelioma outcomes

• Date : 25/03/2021
• 0    
  0

Combining chemotherapy and immunotherapy: key trials in lung cancer

• Date : 25/03/2021
• 0    
  0

Mesothelioma: how will novel immunotherapies impact surgery?

• Date : 25/03/2021
• 0    
  0

PACIFIC 6: durvalumab after sCRT in patients with NSCLC

• Date : 25/03/2021
• 0    
  0

Systemic treatment of non-oncogene addicted NSCLC with brain metastases

• Date : 25/03/2021
• 0    
  0

CAR-T therapy for lung cancer

• Date : 25/03/2021
• 0    
  0

Targeting RET in lung cancer

• Date : 25/03/2021
• 0    
  0

CHEST Congress 2024

• Date : 06/10/2024
• 1829    
  0

2024 World Conference on Lung Cancer

• Date : 07/09/2024
• 2627    
  0

European Association for Bronchology and Interventional Pulmonology EABIP 2024

• Date : 14/05/2024
• 3387    
  0

19th ECFS Basic Science Conference 2024

• Date : 20/03/2024
• 1961    
  0

28e Congrès de Pneumologie de Langue Française

• Date : 26/01/2024
• 5151    
  0